Advertisement

Topics

Centrexion Therapeutics Corporation Company Profile

16:52 EDT 24th June 2018 | BioPortfolio

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.


News Articles [886 Associated News Articles listed on BioPortfolio]

Centrexion raises $67 million to take lead therapy into Phase III

USA-based Pain specialist Centrexion Therapeutics has raised $67 million in a Series D financing to fund…

Centrexion Therapeutics’ CNTX-4975 Receives Fast Track Designation from the FDA for Treatment of Knee Osteoarthritis Pain

BOSTON–(BUSINESS WIRE)–Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that t...

Centrexion secures funding to begin trial of knee osteoarthritis pain drug

Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).

Centrexion’s $67M Series D round to fund Phase 3 pain studies

Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.

Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III.

Centrexion raises $67mm in Series D round to fund Phase III trial for pain candidate CNTX4975

Pain-focused Centrexion Therapeutics Corp. raised $67mm in a Series D financing led by New Enterprise Associates. New and returning investors, including Quan Capital, ArrowMark Partners, investment fu...

Advanced Proteome Therapeutics and ImmunoBiochem Corporation enter into a Collaboration and Option Agreement

VANCOUVER, British Columbia and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Co...

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the U.S...

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1410 Associated Companies listed on BioPortfolio]

Centrexion Therapeutics Corp.

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest, exclusively pain-focused pipelines of non-opioid, n...

Centrexion Therapeutics, Corp.

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-...

Centrexion Therapeutics

Centrexion Therapeutics, Inc., is focused on developing and commercializing new, non-opioid and non-surgical treatments for moderate to severe chronic pain. Centrexion Therapeutic...

Centrexion Therapeutics Corporation

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-o...

Wellstat Therapeutics Corporation

Wellstat Therapeutics™ Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therap...

More Information about "Centrexion Therapeutics Corporation" on BioPortfolio

We have published hundreds of Centrexion Therapeutics Corporation news stories on BioPortfolio along with dozens of Centrexion Therapeutics Corporation Clinical Trials and PubMed Articles about Centrexion Therapeutics Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Centrexion Therapeutics Corporation Companies in our database. You can also find out about relevant Centrexion Therapeutics Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...


Corporate Database Quicklinks



Searches Linking to this Company Record